Published in Cancer Cell on October 18, 2011
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer (2013) 1.72
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol (2013) 1.71
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Antibody-based immunotherapy of cancer. Cell (2012) 1.35
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs (2012) 1.29
CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J Mol Biol (2012) 1.27
The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget (2012) 1.25
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal (2014) 1.20
Synthesis of bispecific antibodies using genetically encoded unnatural amino acids. J Am Chem Soc (2012) 1.14
Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J Virol (2012) 1.12
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS One (2013) 1.05
Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Mol Cancer Ther (2014) 1.05
Regulation of ERBB3/HER3 signaling in cancer. Oncotarget (2014) 1.00
Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines. Mol Cancer (2013) 0.96
Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein Eng Des Sel (2012) 0.94
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer (2013) 0.94
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia (2013) 0.93
Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. MAbs (2013) 0.93
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol (2016) 0.91
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Front Oncol (2016) 0.91
Cellular effects of HER3-specific affibody molecules. PLoS One (2012) 0.91
Pharmacological targeting of the pseudokinase Her3. Nat Chem Biol (2014) 0.90
Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res (2014) 0.90
Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib. Oncogene (2015) 0.90
Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. Cancer Res (2013) 0.89
LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies. J Biol Chem (2012) 0.88
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. J Biol Chem (2014) 0.88
Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol (2012) 0.88
Frontier of therapeutic antibody discovery: The challenges and how to face them. World J Biol Chem (2012) 0.88
Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol (2013) 0.87
Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models. Radiother Oncol (2013) 0.87
The ErbB4 extracellular region retains a tethered-like conformation in the absence of the tether. Protein Sci (2011) 0.87
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol (2016) 0.87
Self-assembled antibody multimers through peptide nucleic acid conjugation. J Am Chem Soc (2012) 0.86
Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer. MAbs (2014) 0.85
HER3 targeting sensitizes HNSCC to cetuximab by reducing HER3 activity and HER2/HER3 dimerization - evidence from cell line and patient derived xenograft models. Clin Cancer Res (2016) 0.85
Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med (2012) 0.84
A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. MAbs (2014) 0.84
The making of bispecific antibodies. MAbs (2017) 0.84
A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res (2015) 0.83
Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine. Microb Cell Fact (2011) 0.83
Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. Onco Targets Ther (2016) 0.82
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci U S A (2013) 0.82
The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs (2016) 0.82
Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PLoS One (2014) 0.81
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther (2016) 0.81
Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology. PLoS One (2013) 0.81
Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities. PLoS One (2014) 0.81
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother (2015) 0.81
Bispecific antibodies in cancer immunotherapy. Hum Vaccin Immunother (2016) 0.80
Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration. Proc Natl Acad Sci U S A (2015) 0.79
Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities. PLoS One (2015) 0.78
FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling. Oncogene (2016) 0.78
A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation. MAbs (2015) 0.78
Identification and characterization of a multispecific monoclonal antibody G2 against chicken prion protein. Protein Sci (2014) 0.77
Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody. Cancer Chemother Pharmacol (2015) 0.77
A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions. MAbs (2014) 0.77
An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo. MAbs (2014) 0.77
Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration. J Biol Chem (2015) 0.77
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. MAbs (2016) 0.77
Identification of sequences common to more than one therapeutic target to treat complex diseases: simulating the high variance in sequence interactivity evolved to modulate robust phenotypes. BMC Genomics (2015) 0.77
The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. Chemother Res Pract (2012) 0.77
Oligoclonal antibodies to target the ErbB family. Expert Opin Biol Ther (2015) 0.77
HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology (2014) 0.76
Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system. MAbs (2015) 0.76
Novel Therapies in Development for Metastatic Colorectal Cancer. Gastrointest Cancer Res (2014) 0.75
Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. Oncotarget (2017) 0.75
Expression, purification, crystallization and preliminary X-ray analysis of the HER3-9E12 Fab complex. Acta Crystallogr F Struct Biol Commun (2014) 0.75
Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer. EBioMedicine (2016) 0.75
Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients. MAbs (2016) 0.75
A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother (2015) 0.75
Development of small molecules targeting the pseudokinase Her3. Bioorg Med Chem Lett (2015) 0.75
Antibodies Targeting Closely Adjacent or Minimally Overlapping Epitopes Can Displace One Another. PLoS One (2017) 0.75
ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLoS One (2017) 0.75
TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. Protein Eng Des Sel (2016) 0.75
In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. Sci Rep (2017) 0.75
The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation. Oncotarget (2016) 0.75
A multispecific monoclonal antibody G2 recognizes at least three completely different epitope sequences with high affinity. Protein Sci (2017) 0.75
Recent advances of bispecific antibodies in solid tumors. J Hematol Oncol (2017) 0.75
siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells. Oncotarget (2017) 0.75
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World J Gastroenterol (2017) 0.75
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med (2008) 12.68
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol (2006) 6.82
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 6.02
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem (2002) 5.63
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res (2008) 5.42
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell (2009) 4.52
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology (2004) 4.25
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 4.11
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med (2002) 4.00
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res (2008) 3.93
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87
PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science (2008) 3.86
Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst (2005) 3.58
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res (2006) 3.34
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
A specificity map for the PDZ domain family. PLoS Biol (2008) 3.16
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol (2010) 3.06
The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol (2007) 3.06
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 3.00
Requirement for coronin 1 in T lymphocyte trafficking and cellular homeostasis. Science (2006) 2.85
Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol (2010) 2.71
Limb remote ischemic preconditioning attenuates lung injury after pulmonary resection under propofol-remifentanil anesthesia: a randomized controlled study. Anesthesiology (2014) 2.66
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell (2004) 2.60
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat (2010) 2.55
Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev (2005) 2.45
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res (2006) 2.40
AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem (2001) 2.35
Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell (2008) 2.35
A multifaceted strategy for implementation of the Ottawa ankle rules in two emergency departments. BMJ (2009) 2.28
Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene (2005) 2.24
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest (2007) 2.19
B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol (2010) 2.17
Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther (2009) 2.16
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol (2004) 2.14
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med (2011) 2.10
Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
The Rad51/RadA N-terminal domain activates nucleoprotein filament ATPase activity. Structure (2006) 2.00
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res (2006) 1.99
Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res (2010) 1.98
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother (2005) 1.98
The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One (2011) 1.96
Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Cochrane Database Syst Rev (2013) 1.91
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res (2013) 1.89
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost (2005) 1.86
Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov (2012) 1.86
Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood (2002) 1.84
Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A (2006) 1.81
Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol (2008) 1.76
A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med (2011) 1.75
PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell (2010) 1.75